Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Study tests if cannabis Self-Medication theory holds up in schizophrenia

NCT ID NCT01964404

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether cannabis or a similar drug (dronabinol) can improve brain reward function in people with schizophrenia who also use cannabis. 263 participants took part to see if these substances help regulate brain circuits linked to motivation and pleasure. The goal was to understand if cannabis acts as a form of self-medication for these patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

263 people

The number who actually took part.

Start date

Jul 2014

Finished

Sep 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Groups 1-3 Participants with schizophrenia and a cannabis use disorder 1. Ages 18 - 55 years 2. Diagnosis of schizophrenia 3. Diagnosis of cannabis abuse or dependence 4. Use of cannabis within the month prior to screening 5. Willing to remain abstinent for the 14 days before the baseline assessments and throughout the two scans. 6. Psychiatrically stable 7. Treated with a stable dose of an antipsychotic medication (except clozapine) for the past month 8. Not seeking treatment for their cannabis use disorder. Group 4 - Control participants with schizophrenia 1. Ages 18 - 55 years 2. Diagnosis of schizophrenia 3. Willing to remain abstinent as described above 4. Psychiatrically stable 5. Treated with a stable dose of an antipsychotic medication (except clozapine) for the past month Groups 5-7 - Control participants with cannabis use disorder 1. Ages 18 - 55 years 2. Diagnosis of cannabis abuse or dependence 3. Use of cannabis within the month prior to screening 4. Willing to remain abstinent as described above 5. Not seeking treatment for their cannabis use disorder. Group 8 - Healthy control participants 1. Ages 18 - 55 years 2. Willing to remain abstinent as described above Exclusion criteria: Groups 1-3 with schizophrenia and a cannabis use disorder 1. Positive symptoms of psychosis (\> 4 \[moderate\]) on any item of the Positive and Negative Syndrome Scale psychosis subscale (once abstinent) except for the hallucination item. We will exclude for a rating \> 5 for this item. 2. Cocaine/stimulant use disorder 3. Pharmacological treatment for addiction 4. Mental retardation 5. History of head injury 6. Metal objects within the body that would contraindicate and MRI 7. Pregnancy or currently nursing 8. Uncontrolled medical condition 9. Taking clozapine 10. Any condition that would contraindicate use of cannabis or dronabinol. 11. History of a seizure disorder Group 4 - Control participants with schizophrenia 1. Positive symptoms of psychosis (\> 4 \[moderate\]) on any item of the Positive and Negative Syndrome Scale psychosis subscale (once abstinent) except for the hallucination item. We will exclude for a rating \> 5 for this item. 2. Any history of a substance use disorder other than nicotine 3. Pharmacological treatment for addiction 4. Mental retardation 5. History of head injury 6. Metal objects within the body that would contraindicate and MRI 7. Pregnancy or currently nursing 8. Uncontrolled medical condition 9. Taking clozapine Groups 5-7 - Control participants with cannabis use disorder 1. Axis I psychiatric diagnosis other than a cannabis use disorder 2. Taking any psychotropic medication 3. Pharmacological treatment for addiction 4. Mental retardation 5. History of head injury 6. Metal objects within the body that would contraindicate and MRI 7. Pregnancy or currently nursing 8. Uncontrolled medical condition 9. History of a seizure disorder Group 8 - Healthy control participants 1. Any Axis I psychiatric diagnosis 2. Taking any psychotropic medication 3. Pharmacological treatment for addiction 4. Mental retardation 5. History of head injury 6. Metal objects within the body that would contraindicate and MRI 7. Pregnancy or currently nursing 8. Uncontrolled medical condition 9. Current tobacco smokers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabis use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire, 03756, United States

  • University of Vermont

    Burlington, Vermont, 05401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.